Renin inhibition and atherosclerosis.
Luft
Friedrich C
FC
Medical Faculty of the Charité, Helios Klinikum-Berlin, Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine, Berlin, Germany. luft@charite.de
D000577:Amides / Q000494:pharmacology; D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D000818:Animals; D050197:Atherosclerosis / Q000209:etiology / Q000517:prevention & control*; D005650:Fumarates / Q000494:pharmacology; D006801:Humans; D051379:Mice; D018345:Mice, Knockout; D008954:Models, Biological; D011973:Receptors, LDL / Q000172:deficiency / Q000235:genetics; D012083:Renin / Q000172:deficiency / Q000235:genetics; D012084:Renin-Angiotensin System / Q000187:drug effects / Q000502:physiology; D000092502:Renin Inhibitors
D000577:Amides; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D005650:Fumarates; D011973:Receptors, LDL; D012083:Renin; D000092502:Renin Inhibitors; C446481:aliskiren